Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
Biohaven's Phase 1 clinical data on BHV-1530, a first-in-class FGFR3-directed ADC with its proprietary TopoIx payload, was selected for an oral presentation at the EORTC-NCI-AACR Symposium in Barcelona, November 18-20, 2026. Early clinical activity includes confirmed partial responses in heavily pretreated patients, with no dose-limiting toxicities and none of the class toxicities seen with approved FGFR kinase inhibitors.
Key figures
- Drug Name
- BHV-1530
- Phase Of Trial
- Phase 1
- Study
- BHV1530-101 (NCT06874335)
- Symposium
- 38th EORTC-NCI-AACR Symposium (ENA 2026)
- Presentation Date
- 19Nov2026
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.